retatrutide nonalcoholic fatty liver disease trial significantly improved health in patients with non-alcoholic liver retatrutide nonalcoholic fatty liver disease

Most insurance plans, including BCBS, provide a drug list of its covered drugs in several tiers

health insurance landscape creates both the opportunity and the constraint: commercial insurance covering GLP-1 for diabetes generates large, well-reimbursed prescription volumes, but coverage for obesity indications varies widely, with Medicare explicitly prohibited from covering weight loss drugs until the Treat and Reduce Obesity Act passes a legislative gap that excludes tens of millions of Medicare beneficiaries from covered GLP-1 obesity access

Tissue repair

For post-GLP-1 patients with mild to moderate skin laxity particularly in the face, neck, abdomen, and arms RF microneedling offers a meaningful improvement without surgical incisions